Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05295433 · ClinicalTrials.gov registry record · Phase 1
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
A Phase 1 study of Methylmalonic Acidemia, sponsored by ModernaTX.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 12
- Study locations
NCT05295433 is a Phase 1 study of Methylmalonic Acidemia that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 56 participants, below the 418-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 5 states.
The verdict
NCT05295433, a Phase 1 study of Methylmalonic Acidemia, is actively recruiting participants, sponsored by ModernaTX.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.
Conditions Studied
Interventions
- DRUG mRNA-3705
Study Locations (12)
Other
- Hôpital Necker - Enfants Malades APHP - Paris
- Erasmus MC - Rotterdam
- Universitair Medisch Centrum Utrecht - Utrecht
- Hospital Universitario 12 de Octubre - Madrid
- Birmingham Children's Hospital NHS Foundation Trust - Birmingham
- Royal Manchester Childrens Hospital - Manchester
California
- UCLA Medical Center - Los Angeles
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- Altman Clinical and Translational Research Institution - San Diego
Alberta
- Stollery Children's Hospital University of Alberta - Edmonton
Ontario
- Hospital For Sick Children - Toronto
Vizcaya
- Hospital Universitario Cruces - Barakaldo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2034-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05295433
The ClinicalTrials.gov registry entry for NCT05295433 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 418-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (87% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Methylmalonic Acidemia appearing as the primary indexed condition, and to 1 intervention - of which mRNA-3705 is the first listed.
NCT05295433 reports 12 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Alberta.
Frequently Asked Questions
What is clinical trial NCT05295433 about?
NCT05295433 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705". The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRN...
What is the current status of trial NCT05295433?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2022-03-08. Estimated completion is 2034-04-02.
What conditions does trial NCT05295433 study?
This clinical trial studies the following conditions: Methylmalonic Acidemia.
What interventions are being tested in trial NCT05295433?
The interventions under investigation include: mRNA-3705 (DRUG).
Who is sponsoring clinical trial NCT05295433?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05295433 being conducted?
This trial has 12 study locations across California, Alberta, Ontario, Vizcaya. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methylmalonic Acidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
ACTIVE NOT RECRUITING · Phase 1
-
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
RECRUITING
-
Clinical and Laboratory Study of Methylmalonic Acidemia
RECRUITING
-
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
ACTIVE NOT RECRUITING
-
"The MaP Study": Mapping the Patient Journey in MMA and PA
COMPLETED
-
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.